These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34336774)

  • 1. SARS-CoV-2 mRNA Vaccine Attitudes as Expressed in U.S. FDA Public Commentary: Need for a Public-Private Partnership in a Learning Immunization System.
    Weitzman ER; Sherman AC; Levy O
    Front Public Health; 2021; 9():695807. PubMed ID: 34336774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines: Perceptions and Attitudes From the Food and Drug Administration Public Commentary.
    Weitzman ER; Sherman AC; Levy O
    Clin Infect Dis; 2022 Aug; 75(Suppl 1):S46-S50. PubMed ID: 35579499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Advisory Committee on Immunization Practices' Ethical Principles for Allocating Initial Supplies of COVID-19 Vaccine - United States, 2020.
    McClung N; Chamberland M; Kinlaw K; Bowen Matthew D; Wallace M; Bell BP; Lee GM; Talbot HK; Romero JR; Oliver SE; Dooling K
    MMWR Morb Mortal Wkly Rep; 2020 Nov; 69(47):1782-1786. PubMed ID: 33237895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine safety - is the SARS-CoV-2 vaccine any different?
    Tau N; Yahav D; Shepshelovich D
    Hum Vaccin Immunother; 2021 May; 17(5):1322-1325. PubMed ID: 33270474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive aspects of the mRNA platform for SARS-CoV-2 vaccines.
    Hajissa K; Mussa A
    Hum Vaccin Immunother; 2021 Aug; 17(8):2445-2447. PubMed ID: 33830862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel.
    Swift MD; Breeher LE; Tande AJ; Tommaso CP; Hainy CM; Chu H; Murad MH; Berbari EF; Virk A
    Clin Infect Dis; 2021 Sep; 73(6):e1376-e1379. PubMed ID: 33900384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Overview Of Vaccine Development, Approval, And Regulation, With Implications For COVID-19.
    Kesselheim AS; Darrow JJ; Kulldorff M; Brown BL; Mitra-Majumdar M; Lee CC; Moneer O; Avorn J
    Health Aff (Millwood); 2021 Jan; 40(1):25-32. PubMed ID: 33211535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered
    Elia U; Ramishetti S; Rosenfeld R; Dammes N; Bar-Haim E; Naidu GS; Makdasi E; Yahalom-Ronen Y; Tamir H; Paran N; Cohen O; Peer D
    ACS Nano; 2021 Jun; 15(6):9627-9637. PubMed ID: 33480671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 Vaccines: A Primer for Clinicians.
    Romero JR; Bernstein HH
    Pediatr Ann; 2020 Dec; 49(12):e532-e536. PubMed ID: 33290571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In brief: Third dose of mRNA-based COVID-19 vaccines for immunocompromised persons.
    Med Lett Drugs Ther; 2021 Sep; 63(1633):145-146. PubMed ID: 34550960
    [No Abstract]   [Full Text] [Related]  

  • 11. A Case of Hypophysitis Following Immunization With the mRNA-1273 SARS-CoV-2 Vaccine.
    Murvelashvili N; Tessnow A
    J Investig Med High Impact Case Rep; 2021; 9():23247096211043386. PubMed ID: 34553641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temporal Associations Between Immunization With the COVID-19 mRNA Vaccines and Myocarditis: The Vaccine Safety Surveillance System Is Working.
    Navar AM; McNally E; Yancy CW; O'Gara PT; Bonow RO
    JAMA Cardiol; 2021 Oct; 6(10):1117-1118. PubMed ID: 34185044
    [No Abstract]   [Full Text] [Related]  

  • 13. Update From the Advisory Committee on Immunization Practices.
    O Leary ST; Maldonado YA; Kimberlin DW
    J Pediatric Infect Dis Soc; 2020 Dec; 9(6):645-649. PubMed ID: 33180938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early COVID-19 First-Dose Vaccination Coverage Among Residents and Staff Members of Skilled Nursing Facilities Participating in the Pharmacy Partnership for Long-Term Care Program - United States, December 2020-January 2021.
    Gharpure R; Guo A; Bishnoi CK; Patel U; Gifford D; Tippins A; Jaffe A; Shulman E; Stone N; Mungai E; Bagchi S; Bell J; Srinivasan A; Patel A; Link-Gelles R
    MMWR Morb Mortal Wkly Rep; 2021 Feb; 70(5):178-182. PubMed ID: 33539332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating and Deploying Covid-19 Vaccines - The Importance of Transparency, Scientific Integrity, and Public Trust.
    Schwartz JL
    N Engl J Med; 2020 Oct; 383(18):1703-1705. PubMed ID: 32966716
    [No Abstract]   [Full Text] [Related]  

  • 17. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
    Frederiksen LSF; Zhang Y; Foged C; Thakur A
    Front Immunol; 2020; 11():1817. PubMed ID: 32793245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dermatology patients on biologics and certain other systemic therapies should receive a "booster" messenger RNA COVID-19 vaccine dose: A critical appraisal of recent Food and Drug Administration and Advisory Committee on Immunization Practices recommendations.
    Waldman RA; Grant-Kels JM
    J Am Acad Dermatol; 2021 Nov; 85(5):1113-1116. PubMed ID: 34437985
    [No Abstract]   [Full Text] [Related]  

  • 19. The Risk of Resurgence in Vaccine-Preventable Infections Due to Coronavirus Disease 2019-Related Gaps in Immunization.
    Feldman AG; O'Leary ST; Danziger-Isakov L
    Clin Infect Dis; 2021 Nov; 73(10):1920-1923. PubMed ID: 33580243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine.
    Benotmane I; Gautier-Vargas G; Cognard N; Olagne J; Heibel F; Braun-Parvez L; Martzloff J; Perrin P; Moulin B; Fafi-Kremer S; Caillard S
    Kidney Int; 2021 Jun; 99(6):1498-1500. PubMed ID: 33887315
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.